By establishing a tumor specific IHC panel (e.g., for lung adenocarcinomas: thyroid transcription factor-1 (TTF-1), CD68 and PD-L1), patients who can potentially benefit from immune checkpoint blockade therapy could be identified by using only one tissue slide, sparing tissue for further diagnostics. The gene discussed is CD68; the disease is lung adenocarcinoma.